Completed PHASE4 INTERVENTIONAL 2-arm NCT01013103

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

Effects of Atorvastatin on Endothelial Function, Vascular and Myocardial Redox State in High Cardiovascular Risk Patients

Sponsor: Hippocration General Hospital

Conditions Atherosclerosis Coronary Artery Disease Endothelial Dysfunction HMG-CoA Reductase Inhibitor Toxicity Oxidative Stress

Interventions Atorvastatin vs Placebo Atorvastatin, high vs low dose

Updated 6 times since 2017 Last updated: Mar 16, 2012 Started: Oct 31, 2007 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Atherosclerosis and Coronary Artery Disease and is currently completed. Hippocration General Hospital leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hippocration General Hospital

Data source: Hippocration General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece